Nordic Pharma, a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the United States. LACRIFILL is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

According to Nordic Pharma, LACRIFILL allows patient’s eyes to be bathed in their own natural tears. It is customized for each individual patient and provides a full fill of the canalicular system.

LACRIFILL is administered through an in-office procedure, which is reimbursed through the existing CPT code (68761), and the results last for 6 months.